Fujifilm may cut 240 workers and rebuild early-stage biologics, CGT unit
Fujifilm Diosynth Biotechnologies is restructuring its small-scale business unit and potentially laying off as many as 240 staffers as reduced investments for early-stage assets continue. The workforce...
View ArticleGSK offers glimpse at positive Phase 3 urogenital gonorrhea data for...
Two months after its urogenital gonorrhea antibiotic hit the primary endpoint in a registrational trial, GSK is providing a closer look at results as it gears up for regulatory filings in 2025. The...
View ArticleClik here to view.
Canaan adds $100M+ to boost biopharma investing, brings on former Pfizer exec
Canaan, a decades-old tech and life sciences venture capital firm, plans to invest more heavily in biopharma going forward. The Menlo Park, CA-based firm added more than $100 million to its 13th fund...
View ArticleLilly plans for Zepbound label expansion into sleep apnea after Phase 3 win
Eli Lilly’s weight loss drug Zepbound hit the primary endpoints in two Phase 3 trials for adults with obstructive sleep apnea and obesity, setting the stage for the first potential approval of a drug...
View ArticleClik here to view.
Sanofi's trimmed oncology plans lead to $3B biobucks dent for IGM
Sanofi’s oncology pruning will lead to the evaporation of an estimated $3 billion in potential biobucks for partner IGM Biosciences. The French pharma giant has amended its $6.15 billion biobuck pact...
View ArticleIntra-Cellular aims to raise $500M; Lilly’s Prevail cuts three partnered...
Plus, news about TScan Therapeutics, Connect BioPharma, Theolytics and Ultimovacs: Intra-Cellular Therapies seeks $500M offering: Shortly after disclosing a Phase 3 win in depression, which could lead...
View ArticleClik here to view.
Sage nixes program for Parkinson’s disease after Phase 2 failure
Sage Therapeutics is terminating the development of its drug dalzanemdor in Parkinson’s disease after a mid-stage test ended in disappointment. The Phase 2 PRECEDENT trial compared the drug with...
View ArticleFujifilm is all in on ADCs, to sell ‘trust’ to boost manufacturing revenues
Fujifilm Diosynth Biotechnologies will receive “aggressive” investment over the next three years from its parent company to lift revenues, as the CDMO arm emphasizes its track record and “trust” as...
View ArticleClik here to view.
A majority of pharma and biotech companies prohibit ChatGPT use, survey finds
Most pharma and biotech companies ban or restrict the use of ChatGPT by their employees, according to a recent survey. Half of pharma and biotech companies restrict its use, but that jumps to 65% when...
View ArticleLilly, insulin users end $13.5M settlement plan following federal judge's...
A settlement between Eli Lilly and insulin users has collapsed after a federal judge’s ruling that denied class certification for the lawsuit. The original settlement stemmed from a 2017 lawsuit in...
View ArticleClik here to view.
GSK unveils long-term Shingrix data as shingles competition heats up
GSK’s market-leading Shingrix vaccine proved effective against shingles more than 10 years post-administration, creating a new hurdle for a number of potential competitors. Shingrix was 82% effective...
View ArticleAncestry cut 6% of workforce as genealogy giant struggles with subscription...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Genealogy giant Ancestry laid off 81 employees as it continues to wrestle with growing the revenue it...
View ArticleCerevel notches Phase 3 Parkinson's win ahead of AbbVie transaction closing
As it waits for its acquisition by AbbVie to finalize, Cerevel reported a Phase 3 win for one of its programs in Parkinson’s disease. Patients taking the biotech’s once-daily drug, called tavapadon, on...
View ArticleClik here to view.
Metsera launches with $290M to take on obesity giants
A new startup aims to challenge Novo Nordisk and Eli Lilly’s duopoly atop today’s market for obesity drugs. The startup Metsera officially launched Thursday, announcing $290 million in an initial...
View ArticleClik here to view.
Pathios rakes in $25M to help start trials for GPR65 inhibitor
Pathios Therapeutics drew in $25 million for the first close of a Series B raise that should help the UK biotech test its first-in-class solid tumor candidate in clinical trials by the end of the year....
View Article23andMe's CEO files plan to take company private
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) DNA testing company 23andMe’s CEO Anne Wojcicki is looking to take the company private, according to a...
View ArticleClik here to view.
J&J, Bristol Myers race to amplify CAR-T manufacturing to meet label...
Johnson & Johnson and Bristol Myers Squibb are individually gearing up their lentiviral production and CAR-T product capacities following their recent label expansions in multiple myeloma. J&J,...
View ArticleBiohaven’s $230M offering; Plus, three new PIPEs
Read on for news about Benitec Biopharma, Korro Bio, Zura Bio, Ocular Therapeutix and SK biopharmaceuticals: Biohaven to seek $230M public offering: The company’s offering follows an update to its...
View ArticleClik here to view.
Bruker to acquire troubled spatial biology company NanoString for $392M
A company at the center of one of the hottest technologies in life science research, and one of the most vicious patent battles among makers of lab instruments, has closed a chapter. NanoString...
View ArticleClik here to view.
Corner Therapeutics to hyperactivate ‘the brains of the immune system’ with...
Corner Therapeutics’ $54 million Series A will be used to bring new immunotherapies for cancer and infectious diseases into the clinic, the company said Thursday. Steve Altschuler The startup is led by...
View Article